Egyptian Journal of Medical Human Genetics

Table 1 Clinical and demographic data of patient population (N = 160)

From: An exploratory pharmacogenetic screening of SLC22A6, SLC22A8, ABCC4 and ABCC10 genes in a cohort of Ghanaian HBV patients

Gender	N (%)	p value
Male	76 (47.50)	0.528
Female	84 (52.50)
Age
Male median age (IQR)	31 (24–40)	0.054
Female median age (IQR)	35 (28–43)
Herbal medicine usage
Yes	12 (7.64)	0.001*
No	140 (92.36)
Treatment
TDF	17 (10.62)	0.001*
Without treatment	143 (89.38)
Creatinine (mg/dL) median (IQR)
TDF	0.32 (0.29–0.36)	0.305
Without treatment	0.34 (0.27–0.47)
Classification
Acute	47 (29.38)	0.001*
Chronic	113 (70.62)
Duration versus treatment
< 6 months + TDF	3 (5.67)	0.001*
< 6 months + without treatment	44 (94.33)
> 6 month + TDF	14 (9.62)	0.001*
> 6 month + without treatment	99 (90.38)
VL (copies/mL)
0–299	57 (35.62)	0.001*
300–9999	84 (52.50)
10,000–999991	15 (9.38)
> 100,000	4 (2.50)
eGFR, mL/min/1.73 m²
Stage 1 (> 90 mL/min/1.73 m²)	50 (31.25)	0.001*
Stage 2 (> 60–89.99 mL/min/1.73 m²)	72 (45.00)
Stage 3a (> 45–59.99 mL/min/1.73 m²)	23 (14.38)
Stage 3b (> 30– 44.99 mL/min/1.73 m²)	10 (6.25)
Stage 4(15–29.99 mL/min/1.73 m²)	3 (1.88)
Stage 5 (< 15 mL/min/1.73 m²)	2 (1.25)

Continuous variables are expressed as median (IQR) while categorical variables are expressed as absolute values and or frequencies
TDF Tenofovir disoproxil fumarate, eGFR Estimated glomerular filtration rate, IQR Interquartile range
*statistically significant

Back to article page